Award
NIH Reporter #1R42CA310337-01
Dual Acting Bone Defenders for Inhibiting Cancer Mediated Bone Destruction
Recipient
Not specified
Award Amount
$400,000.00
Ceiling
$400,000.00
Awarded
September 17, 2026
Identifier
1R42CA310337-01
Award for developing a therapeutic to inhibit cancer-mediated bone destruction, including synthesis and toxicity studies, with a total amount of $400,000.
Description
This project aims to develop a first-in-class therapeutic to inhibit bone destruction caused by cancer, with a focus on prostate, breast, and lung cancers. The project includes scale-up synthesis, toxicity studies, and IND submission.